Home>
US Stocks>
Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc share price today

(ADAP)

Adaptimmune Therapeutics Plc share price is $0.58 & ₹49.41 as on 25 Dec 2024, 2.30 'hrs' IST

$0.58

▲

-0.01

(-1.56%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Adaptimmune Therapeutics Plc share price in Dollar and Rupees. Guide to invest in Adaptimmune Therapeutics Plc from India. Also see the sentimental analysis on Indian investors investing in Adaptimmune Therapeutics Plc. Get details on the Indian mutual funds that are investing in Adaptimmune Therapeutics Plc. Get Analyst recommendations and forecasts along with all the Adaptimmune Therapeutics Plc's financials.

Adaptimmune Therapeutics Plc share price movements

Today's Low: $0.58
Today's High: $0.61
$0.58
0.84%
Downside
Day's Volatility :5.04%
Upside
4.23%
52 Weeks Low: $0.50
52 Weeks High: $2.05
$0.58
13.71%
Downside
52 Weeks Volatility :75.59%
Upside
71.71%

Adaptimmune Therapeutics Plc Returns

Period	Adaptimmune Therapeutics Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-38.23%	-8.7%	0.0%
6 Months	-40.99%	-5.0%	0.0%
1 Year	-19.5%	3.2%	0.0%
3 Years	-85.35%	0.0%	-21.1%

Adaptimmune Therapeutics Plc Key Statistics

in dollars & INR

Previous Close	$0.588
Open	$0.581
Today's High	$0.6056
Today's Low	$0.5751
Market Capitalization	$150.5M
Today's Volume	$1.2M
52 Week High	$2.05
52 Week Low	$0.5005
Revenue TTM	$141.5M
EBITDA	$-72.9M
Earnings Per Share (EPS)	$-0.17
Profit Margin	-51.25%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-65.04%

How to invest in Adaptimmune Therapeutics Plc from India?

It is very easy for Indian residents to invest directly in Adaptimmune Therapeutics Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Adaptimmune Therapeutics Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Adaptimmune Therapeutics Plc or ADAP on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Adaptimmune Therapeutics Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Adaptimmune Therapeutics Plc shares which would translate to 1.469 fractional shares of Adaptimmune Therapeutics Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Adaptimmune Therapeutics Plc, in just a few clicks!

Returns in Adaptimmune Therapeutics Plc for Indian investors in Rupees

Investment Value

₹1,00,000

Adaptimmune Therapeutics Plc investment value today

Current value as on today

₹82,982

Returns

₹17,018

(-17.02%)

Returns from Adaptimmune Therapeutics Plc Stock

₹19,444 (-19.44%)

Dollar Returns

₹2,426 (+2.43%)

Indian investors sentiment towards Adaptimmune Therapeutics Plc

21%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Adaptimmune Therapeutics Plc on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 21% more investors are searching Adaptimmune Therapeutics Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Adaptimmune Therapeutics Plc

Matrix Capital Management Company, LLC
14.73%
EcoR1 Capital, LLC
10.71%
NEA Management Company, LLC
6.67%
Baillie Gifford & Co Limited.
6.56%
Long Focus Capital Management, LLC
5.20%
Partner Fund Management LP
3.91%

Analyst Recommendation on Adaptimmune Therapeutics Plc

Buy

69%Buy

23%Hold

7%Sell

Based on 13 Wall street analysts offering stock ratings for Adaptimmune Therapeutics Plc(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Adaptimmune Therapeutics Plc

What analysts predicted

Upside of 290.81%

Current:

$0.58

Target:

$2.27

Insights on Adaptimmune Therapeutics Plc

Price Movement
In the last 7 days, ADAP stock has moved down by -4.5%
Decreasing Revenue
Revenue is down for the last 2 quarters, 128.23M → 40.90M (in $), with an average decrease of 68.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 69.52M → -17.61M (in $), with an average decrease of 125.3% per quarter
ADAP vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 27.3% return, outperforming this stock by 11.5%
ADAP vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 111.1%
Price to Sales
ForADAP every $1 of sales, investors are willing to pay $1.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.7 for every $1 of sales.

Adaptimmune Therapeutics Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$59.5M	↑ 57.28%
Net Income	$-95.5M	↑ 36.18%
Net Profit Margin	-160.51%	↑ 24.88%

	FY19	Y/Y Change
Revenue	$1.1M	↓ 98.11%
Net Income	$-137.2M	↑ 43.61%
Net Profit Margin	-12.2K%	↓ 12064.53%

	FY20	Y/Y Change
Revenue	$4.0M	↑ 252.76%
Net Income	$-130.1M	↓ 5.16%
Net Profit Margin	-3.3K%	↑ 8938.23%

	FY21	Y/Y Change
Revenue	$6.1M	↑ 55.36%
Net Income	$-158.1M	↑ 21.52%
Net Profit Margin	-2.6K%	↑ 715.82%

	FY22	Y/Y Change
Revenue	$27.1M	↑ 341.5%
Net Income	$-165.5M	↑ 4.66%
Net Profit Margin	-609.46%	↑ 1961.53%

	FY23	Y/Y Change
Revenue	$60.3M	↑ 122.05%
Net Income	$-113.9M	↓ 31.18%
Net Profit Margin	-188.9%	↑ 420.56%

	Q2 FY23	Q/Q Change
Revenue	$5.1M	↓ 89.22%
Net Income	$-21.4M	↓ 2164.58%
Net Profit Margin	-416.94%	↓ 419.12%

	Q3 FY23	Q/Q Change
Revenue	$7.3M	↑ 42.67%
Net Income	$-45.6M	↑ 113.2%
Net Profit Margin	-623.05%	↓ 206.11%

	Q4 FY23	Q/Q Change
Revenue	$233.0K	↓ 96.82%
Net Income	$-48.3M	↑ 5.99%
Net Profit Margin	-20.7K%	↓ 20120.28%

	Q1 FY24	Q/Q Change
Revenue	$5.7M	↑ 2336.82%
Net Income	$-48.5M	↑ 0.35%
Net Profit Margin	-854.23%	↑ 19889.1%

	Q2 FY24	Q/Q Change
Revenue	$128.2M	↑ 2158.38%
Net Income	$69.5M	↓ 243.33%
Net Profit Margin	54.22%	↑ 908.45%

	Q3 FY24	Q/Q Change
Revenue	$40.9M	↓ 68.1%
Net Income	$-17.6M	↓ 125.34%
Net Profit Margin	-43.07%	↓ 97.29%

	FY18	Y/Y Change
Profit	$59.5M	↑ 57.28%

	FY19	Y/Y Change
Profit	$-96.4M	↓ 261.97%

	FY20	Y/Y Change
Profit	$-87.6M	↓ 9.1%

	FY21	Y/Y Change
Profit	$-104.9M	↑ 19.78%

	FY22	Y/Y Change
Profit	$-100.6M	↓ 4.16%

	FY23	Y/Y Change
Profit	$50.4M	↓ 150.13%

	Q2 FY23	Q/Q Change
Profit	$2.9M	↓ 93.68%

	Q3 FY23	Q/Q Change
Profit	$4.4M	↑ 53.72%

	Q4 FY23	Q/Q Change
Profit	$-2.6M	↓ 159.45%

	Q1 FY24	Q/Q Change
Profit	$2.8M	↓ 207.87%

	Q2 FY24	Q/Q Change
Profit	$125.6M	↑ 4308.65%

	Q3 FY24	Q/Q Change
Profit	$40.9M	↓ 67.44%

	FY18	Y/Y Change
Operating Cash Flow	$-104.4M	↑ 92.19%
Investing Cash Flow	$-17.5M	↓ 86.15%
Financing Cash Flow	$102.7M	↓ 0.85%

	FY19	Y/Y Change
Operating Cash Flow	$-112.5M	↑ 7.78%
Investing Cash Flow	$94.9M	↓ 643.88%
Financing Cash Flow	$366.0K	↓ 99.64%

	FY20	Y/Y Change
Operating Cash Flow	$-53.6M	↓ 52.37%
Investing Cash Flow	$-278.9M	↓ 393.77%
Financing Cash Flow	$340.1M	↑ 92810.11%

	FY21	Y/Y Change
Operating Cash Flow	$10.7M	↓ 120.02%
Investing Cash Flow	$75.8M	↓ 127.18%
Financing Cash Flow	$3.3M	↓ 99.03%

	FY22	Y/Y Change
Operating Cash Flow	$-141.8M	↓ 1421.36%
Investing Cash Flow	$89.1M	↑ 17.59%
Financing Cash Flow	$12.9M	↑ 291.33%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-43.8M	↑ 17.38%
Investing Cash Flow	$2.7M	↑ 0.0%
Financing Cash Flow	$14.0K	↓ 92.86%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-45.2M	↑ 3.19%
Investing Cash Flow	$57.3M	↑ 2027.17%
Financing Cash Flow	$596.0K	↑ 4157.14%

Adaptimmune Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Adaptimmune Therapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Adaptimmune Therapeutics Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Adaptimmune Therapeutics Plc	-16.97%	-40.99%	-19.5%	-85.35%	-50.1%
Regeneron Pharmaceuticals, Inc.	-4.68%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-5.49%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.08%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-11.59%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Adaptimmune Therapeutics Plc	NA	NA	0.11	-0.14	-0.65	-0.16	NA	0.17
Regeneron Pharmaceuticals, Inc.	17.7	17.7	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Adaptimmune Therapeutics Plc	Buy	$150.5M	-50.1%	NA	-51.25%
Regeneron Pharmaceuticals, Inc.	Buy	$78.6B	91.19%	17.7	33.61%
Biontech Se	Buy	$27.2B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.2B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$104.4B	86.41%	32.84	-4.51%

About Adaptimmune Therapeutics Plc

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Organization	Adaptimmune Therapeutics Plc
Employees	449
CEO	Mr. Adrian G. Rawcliffe
Industry	Health Technology

Management People of Adaptimmune Therapeutics Plc

Name	Title
Mr. Adrian G. Rawcliffe	CEO, Principal Accounting Officer & Director
Dr. Helen Katrina Tayton-Martin MBA, Ph.D.	Co-Founder & Chief Business & Strategy Officer
Mr. Gavin Hilary James Wood ACA, BA (Hons)	Chief Financial Officer
Mr. William C. A. Bertrand Jr., Esq., J.D.	COO & Chief Compliance Officer
Dr. Elliot Norry B.A., M.D.	Chief Medical Officer
Ms. Joanna Brewer Ph.D.	Chief Scientific Officer
Dr. Juli P. Miller Ph.D.	VP of Corporate Affairs & Investor Relations
Ms. Kerry Sharp	Senior VP & General Council
Ms. Dana Lynch	Senior Director of Corporate Communications
Mr. John Lunger	Chief Patient Supply Officer

Important FAQs about investing in Adaptimmune Therapeutics Plc from India :

What is Adaptimmune Therapeutics Plc share price today?

Adaptimmune Therapeutics Plc share price today stands at $0.58, Open: $0.58 ; Previous Close: $0.59 ; High: $0.61 ; Low: $0.58 ; 52 Week High: $2.05 ; 52 Week Low: $0.50. The stock opens at $0.58, after a previous close of $0.59. The stock reached a daily high of $0.61 and a low of $0.58, with a 52-week high of $2.05 and a 52-week low of $0.50.

Can Indians buy Adaptimmune Therapeutics Plc shares?

Yes, Indians can invest in the Adaptimmune Therapeutics Plc (ADAP) from India.

With INDmoney, you can buy Adaptimmune Therapeutics Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Adaptimmune Therapeutics Plc at zero transaction cost.

How can I buy Adaptimmune Therapeutics Plc shares from India?

It is very easy to buy Adaptimmune Therapeutics Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Adaptimmune Therapeutics Plc be purchased?

Yes, you can buy fractional shares of Adaptimmune Therapeutics Plc with INDmoney app.

What are the documents required to start investing in Adaptimmune Therapeutics Plc stocks?

To start investing in Adaptimmune Therapeutics Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.